Royalty Report: Drugs, Biotechnology – Collection: 5565


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5565

License Grant
The Licensor hereby grants to the Licensee the exclusive right to use the Cascade Process, or part thereof to manufacture in the Production Facility and any Additional Production Facilities in the territory, and distribute and sell in the territory, the Proteins, Additional Proteins and Products.
License Property
The Licensor has the exclusive right to License an improved plasma protein recovery technology defined hereunder as the Cascade Process, and wishes to grant certain rights in such technology to the Licensee in order to allow the Licensee to manufacture proteins and related products, all in accordance with the terms and conditions hereof.

This Cascade process is based on affinity chromatography and significantly increases protein yields, which allows for substantial increases in revenue and profitability per liter of plasma as compared to the established Cohn cold ethanol fractionation process currently in use. The Cascade process involves taking plasma and passing it through a series of affinity chromatography columns that are filled with resins that are each highly specific and selective for different plasma protein. The proteins of interest are captured on each of the different resins while the unbound plasma components flow through the column and form the feed to the next affinity column. This process allows the individual proteins of interest to be washed off the affinity columns for subsequent viral inactivation and down stream processing and finishing.

Field of Use
An exclusive North American license was granted for a new so-called cascade blood purification process developed by Montreal-based licensor and the American Red Cross to recover proteins.  The cascade process is said to 'significantly improve the yield and product recovery of valuable proteins isolated from human plasma' compared with established fractionation techniques from human plasma.  Proteins shall mean each of the Fibrinogen, APO-A-1, VWF/FVIII, hSA, AlPI, IVIG, in bulk active form, which can be isolated from the Raw Material using the Cascade Process.

IPSCIO Record ID: 26140

License Grant
Licensee announced that it had entered into the MOU obtaining an exclusive North American license for the novel cascade purification process for plasma separation (the Cascade) developed by Licensor and its strategic partner, the American National Red Cross.
License Property
The MOU provides that Licensee and Licensor will use their best commercial efforts to define and execute all necessary definitive agreements for the strategic alliance within 45 days of executing the MOU.

The Cascade process is a novel plasma separation technology that is designed to recover specific proteins from human plasma. Current technology for the recovery of these proteins is relatively inefficient resulting in lower yields than can be achieved with the Cascade. As a result, we intend to produce these proteins more efficiently and at lower cost than other suppliers using traditional plasma separation technologies. Additionally, the Cascade has the potential to recover proteins that are not recoverable using conventional technology, providing additional competitive advantages to us.

Field of Use
The Field of Use applies to recovering valuable proteins from human plasma relating to the healthcare industry.  Licensee is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins. The Company has a broad range of novel therapeutic products in development, including HEMOLINK(TM) (hemoglobin raffimer), an oxygen therapeutic designed to rapidly and safely improve oxygen delivery via the circulatory system. Licensee also is developing additional oxygen therapeutics, a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, and a cell therapy program initially directed to the treatment of cancer. Licensee intends to leverage its expertise in manufacturing blood proteins and its state-of-the-art Meadowpine manufacturing facility to seek additional strategic growth opportunities.

IPSCIO Record ID: 273425

License Grant
Licensor hereby grants to Licensee, under the Licensor Patent Rights, the rights, which shall be exclusive within the Field, to commercialize Finished Product, including to use, have used, offer for sale, sell, have sold, import, and have imported the Finished Product in the Territory.
License Property
Finished Product shall mean any pharmaceutical product Processed on behalf of Licensee hereunder that contains AIG as an active ingredient.

Licensor Patent Rights
US Patent No. 6,955,917 – Chromatographic method for high-yield purification and viral inactivation of antibodies.
US Patent No. 6,307,028 – Chromatographic method for high-yield purification and viral inactivation of antibodies.
US Patent No. 5,886,154 – Chromatographic method for high-yield purification and viral inactivation of antibodies.

AIG shall mean Anthrax Immune Globulin derived from AIG Source Plasma.
AIG Source Plasma shall mean anthrax immune human plasma, as defined under Applicable Law, collected by or on behalf of Licensee. AIG Source Plasma shall exclude By-Products.

Field of Use
Field shall mean the prevention, treatment or therapy of anthrax infection in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.